Cite
HARVARD Citation
Clement, P. et al. (2021). Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. European journal of cancer. pp. 1-12. [Online].